Kala Bio, Inc. (KALA) Stock Price & Analysis
Kala Bio, Inc. (KALA) rose 2.62% to USD 2.35 as of June 10, 2026 at 02:39 UTC, according to Nexqual real-time market data.
KALA last closed at USD 2.29; the session ranged USD 2.21–2.42 on volume of 84,162 shares. Market capitalization is $43.69M, with a 52-week range of USD 2.03–1,030 (NCM). Source: Nexqual, June 10, 2026 at 02:39 UTC.
Key Statistics (as of June 10, 2026 at 02:39 UTC)
| Price | USD 2.35 |
|---|---|
| Change | ▲ 2.62% (up) |
| Previous Close | USD 2.29 |
| Open | USD 2.34 |
| Day Range | USD 2.21 – 2.42 |
| 52-Week Range | USD 2.03 – 1,030 |
| Volume | 84,162 shares |
| Market Cap | $43.69M |
| Exchange | NCM |
Technical Analysis (KALA)
Nexqual's technical model rates KALA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.71 (oversold) |
| vs SMA50 | Below (USD 5.6) |
| MACD | -1.02 (negative) |
Analyst Ratings (KALA)
Wall Street analysts rate KALA "None", per Nexqual as of June 10, 2026 at 02:39 UTC.
| Consensus Rating | None |
|---|
Earnings (KALA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -53.5 vs est -50.5 ▼ miss |
| 2025-06-30 | USD -65.94 vs est -102 ▲ beat |
| 2025-03-31 | USD -50.66 vs est -127 ▲ beat |
| 2024-12-31 | USD -61.58 vs est -123.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financials & Fundamentals (KALA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -238.68% |
| Current Ratio | 7.91 |
| Total Cash | $8.76M |
| Total Debt | $0 |
| Free Cash Flow | $-19.47M |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financial Health Score (KALA)
Nexqual rates Kala Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Critical — ROE -239%, ROA -69.3% |
Ownership (KALA)
| Insider Ownership | +1.30% |
|---|---|
| Institutional Ownership | +0.64% |
| Shares Outstanding | 18.59M |
| Float | 18.59M |
| Short % of Float | +0.38% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Leadership (KALA)
Kala Bio, Inc. is led by Avi Minkowitz (age 37), CEO, CFO & Director, per Nexqual as of June 10, 2026 at 02:39 UTC.
| CEO, CFO & Director | Avi Minkowitz (age 37) |
|---|---|
| Executive Director of Investor Relations & Corporate Communications | Jill S. Steier |
| Executive Director of Account Management | Carl Rennie |
| Executive Director of Trade & Alternate Channels | Patrick Bedell |
Major Backers & Investors (KALA)
Notable institutional backers of Kala Bio, Inc. include Fidelity, according to Nexqual as of June 10, 2026 at 02:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.65% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
From Kala Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States.
- The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
- Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data.
- The company serves biotechnology and pharmaceutical companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| NERV | Minerva Neurosciences, Inc | USD 4.74 | ▼ 4.44% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| ARDX | Ardelyx, Inc. | USD 5.6 | ▲ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:39 UTC. This page is informational and not investment advice.